Did targeted therapy fail cyclooxygenase too?

Journal of Clinical Oncology

Volumn 24, Issue 30, 2006, Pages 4798-4800

  Csiki, Ildiko ^a   Johnson, David H ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; DOCETAXEL; GEMCITABINE; IRINOTECAN; PROSTACYCLIN; PROSTAGLANDIN D2; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN H2; THROMBOXANE A2; ANTINEOPLASTIC AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; PYRAZOLE DERIVATIVE; SULFONAMIDE;

CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG MECHANISM; DRUG TARGETING; EDITORIAL; HUMAN; LUNG NON SMALL CELL CANCER; PATHOGENESIS; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT; ENZYMOLOGY; LUNG TUMOR; NOTE; PATHOPHYSIOLOGY; PATIENT SELECTION; REPRODUCIBILITY; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CYCLOOXYGENASE INHIBITORS; HUMANS; LUNG NEOPLASMS; PATIENT SELECTION; PYRAZOLES; REPRODUCIBILITY OF RESULTS; SULFONAMIDES; TREATMENT OUTCOME;

EID: 33750625292     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.08.0622     Document Type: Editorial

References (23)

1. Brown JR, DuBois RN: Cyclooxygenase as a target in lung cancer. Clin Cancer Res 10:4266s-4269s, 2004
2. Krysan K, Reckamp KL, Sharma S, et al: The potential and rationale for COX-2 inhibitors in lung cancer. Anticancer Agents Med Chem 6:209-220, 2006
3. Wang D, DuBois RN: Prostaglandins and cancer. Gut 55:115-122, 2006
4. Hida T, Kozaki K, Muramatsu H, et al: Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res 6:2006-2011, 2000
5. Lilenbaum R, Socinski MA, Altorki NK, et al: A randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small cell lung cancer. J Clin Oncol 24:4825-4832, 2006
6. Grosch S, Maier TJ, Schiffmann S, et al: Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 98:736-747, 2006
7. Edleman MJ, Watson DM, Wang X, et al: Eicosanoid modulation in advanced non-small cell lung cancer (NSCLC): CALGB 30203. J Clin Oncol 24:370s, 2006 (suppl; abstr 7025)
8. Altorki NK, Keresztes RS, Port JL, et al: Celecoxib, a selective cyclooxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol 21:2645-2650, 2003
9. Reckamp KL, Krysan K, Morrow JD, et al: A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. Clin Cancer Res 12:3381-3388, 2006
10. Murphey LJ, Williams MK, Sanchez SC, et al: Quantification of the major urinary metabolite of PGE(2) by a liquid chromatographic/mass spectrometric assay: Determination of cyclooxygenase-specific PGE(2) synthesis in healthy humans and those with lung cancer. Anal Biochem 334:266-275, 2004
11. Csiki I, Morrow JD, Sandler A, et al: Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: A phase II trial of celecoxib and docetaxel. Clin Cancer Res 11:6634-6640, 2005
12. Gross ND, Boyle JO, Morrow JD, et al: Levels of prostaglandin E metabolite, the major urinary metabolite of prostaglandin E2, are increased in smokers. Clin Cancer Res 11:6087-6093, 2005
13. Subbaramaiah K, Hart JC, Norton L, et al: Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2: Evidence for involvement of ERK1/2 and p38 mitogen-activated protein kinase pathways. J Biol Chem 275:14838-14845, 2000
14. Subbaramaiah K, Marmo TP, Dixon DA, et al: Regulation of cyclooxgenase-2 mRNA stability by taxanes: Evidence for involvement of p38, MAPKAPK-2, and HuR. J Biol Chem 278:37637-37647, 2003
15. Mukherjee D, Nissen SE, Topol EJ: Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286:954-959, 2001
16. Nana-Sinkam P, Golpon H, Keith RL, et al: Prostacyclin in human non-small cell lung cancers. Chest 125:141S, 2004 (suppl 5)
17. Honn KV, Cicone B, Skoff A: Prostacyclin: A potent antimetastatic agent. Science 212:1270-1272, 1981
18. Yoshimatsu K, Altorki NK, Golijanin D, et al: Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer. Clin Cancer Res 7:2669-2674, 2001
19. Ding Y, Tong M, Liu S, et al: NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer. Carcinogenesis 26:65-72, 2005
20. Yang L, Kikuchi T, Amann J, et al: Inhibition of EGFR signaling elevates 15-hydroxyprostaglandin dehydrogenase in non-small cell lung cancer. Proc Am Assoc Cancer Res 47:20, 2006 (abstr 1343)
21. Narumiya S, Sugimoto Y, Ushikubi F: Prostanoid receptors: Structures, properties, and functions. Physiol Rev 79:1193-1226, 1999
22. Ma X, Kundu N, Rifat S, et al: Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis. Cancer Res 66:2923-2927, 2006
23. Yang L, Huang YH, Porta R, et al: Profound reduction in tumor metastasis with selective EP4 receptor antagonism. Cancer Res (in press)